Drug Trial Radar · NCT05293171
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 11, 2021
Primary completion
Jun 1, 2022
Study completion Aug 15, 2022
Sponsor
- Lead sponsor
- BioLineRx, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Celerion
- First posted
- Mar 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will assess the corrected QT (QTc) effects (electrocardiogram \[ECG\]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative to placebo in approximately 40 healthy subjects.
Conditions
- Healthy Subjects
Interventions
1.25 mg/kg BL-8040 + BL-8040-matching placeboDrug
Administered via subcutaneous (SC) injection
2 mg/kg BL-8040Drug
Administered via subcutaneous (SC) injection
BL-8040-matching placeboDrug
Administered subcutaneous (SC) injection
400 mg Moxifloxacin (1x400 mg tablet)Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- QTc Effect of Single Subcutaneous (SC) Injections of Motixafortide (BL-8040) 1.25 mg/kg and 2 mg/kgTime frame: Cardiodynamic ECG recordings on Day 1 (day of dosing) at different time points prior to dosing and up to 24 hours post-dose in each period (each period is 24 hours long, a total of 4 periods)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Phoenix, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.